Asthma in Children
Conditions
Brief summary
This study is a 24-week, randomized, parallel group comparative effectiveness study to evaluate the risk of stepping down therapy for patients with well-controlled asthma treated with combination Inhaled corticosteroids (ICS) and Leukotriene receptor antagonist（LTRA).
Detailed description
Asthma guidelines recommend stepping down therapy once asthma is controlled for at least 3 months. Leukotriene receptor antagonist（LTRA). For children with mild persistent asthma, ICS twice a day combined with LTRA can be used for treatment, but there is no consensus on how to reduce drugs in patients with asthma that is well controlled (reducing the dose of ICS or stopping montelukast). We propose a 24-week, randomized, parallel group comparative effectiveness study comparing three approaches in patients with asthma well-controlled for at least three months on combination ICS and LTRA: Halve the dose of ICS firstly and then stop ICS with montelukast only, stop montelukast firstly and then halve the dose of ICS, and halve the dose of ICS firstly and then stop montelukast. Our goal is to compare the rate of treatment failure and determine the optimal treatment strategy. Additional goals include assessing risk factors for step-down failure.
Interventions
DRUGFluticasone propionate inhaled aerosol
The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.
Sponsors
Xijing Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 14 Years
Healthy volunteers
No
Inclusion criteria
* age 4-14 years * patients had mild to moderate persistent asthma. Patients have treated with low-dose inhaled corticosteroids (equivalent to Fluticasone propionate inhaled aerosol 250 ug/ day) combined with Leukotriene receptor antagonist (Montelulast) at least 6 months of and had no symptoms of asthma for nearly 3 months under well asthma control(Asthma Control Test (ACT) score more than or equal to 20). * patients did not suffer from other acute or chronic diseases that may affect their growth and development
Exclusion criteria
* patients with severe persistent asthma or mild persistent asthma failed to be well controlled by low-dose ICS after starting treatment * suffer from other diseases: Congenital heart disease, chronic infectious disease, protracted diarrhea, congenital airway disease, congenital vascular ring malformation, congenital immune deficiency, tracheal foreign body, bronchial lymph node tuberculosis and gastroesophageal reflux etc. * patients with poor compliance stop medication or fail to take medication on time.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Asthma Control Test (ACT) score | Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 weeks | Change in participant's Asthma Control Test (ACT) score |
| Number of Participants Who Experienced asthma exacerbation or used oral/intravenous corticosteroids as needed | Baseline (Week 0) to Week 12 | Participants Experienced asthma exacerbation or used oral/intravenous corticosteroids as needed |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Forced vital capacity in predicted(FVC%pred) | Baseline, 12 weeks and 24 weeks | Change in participant's Forced vital capacity in predicted |
| Fractional exhaled Nitric Oxide, FeNO | Baseline, 12 weeks and 24 weeks | Change in participant's Fractional exhaled Nitric Oxide |
| Peak expiratory flow (PEF) | Baseline, 12 weeks and 24 weeks | Change in participant's Peak expiratory flow |
| Maximal mid expiratory flow in predicted(MMEF%pred) | Baseline, 12 weeks and 24 weeks | Change in participant's Maximal mid expiratory flow in predicted |
| Forced expiratory volume in one second in predicted（FEV1%pred） | Baseline, 12 weeks and 24 weeks | Change in participant's Forced expiratory volume in one second in predicted |
Countries
China
Contacts
Primary ContactXin Sun, doctor
Outcome results
None listed